Previous PostJune 6, 2025: Eric Soyer, directeur financier Maat Pharma : "demande d'autorisation de mise sur le marché" - Lyon Décideurs (French Only)
Next PostJune 2, 2025: MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease